Recent Updates
Recently added Catalysts

APD356-lorcaserin

Phase 2

Smoking Cessation | Small molecule | Other |Pfizer, Inc.|Last Updated: Apr 15, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment603
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02044874A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking CessationPHASE2 COMPLETED 603Mar 1, 2014Nov 1, 2014Apr 15, 2019 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
APD356-lorcaserin hydrochlorideDRUG -
PlaceboDRUG -
Unlock Study Design Details